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Abstract 
This short report describes the case of a young adult male who had smoked a synthetic 
cannabinoid legal high product called ’Exodus Damnation’.  The patient’s presentation was 
atypical from that described in the literature, with hypotension and hypoxaemia.  Of note was 
the rapid recovery after prehospital intervention with high flow oxygen therapy and intravenous 
fluids.  The patient refused on going care, despite repeated advice to attend the Emergency 
Department. The distinct lack of specialist support and referral to drug treatment for this patient 
population, with whom ambulance services are coming into contact with increasing frequency, 
is reported.  For those patients with the capacity to refuse on-going care, ambulance services 
may be in an opportune position to actively promote referral to support services for these 
vulnerable individuals. 
 
Key words: Legal high, new psychoactive substances, Exodus damnation, synthetic 
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Introduction 
 
We report the case of an 18-year-old male found in a collapsed state after smoking a legal high 
product known as ‘Exodus Damnation’, which has previously been associated with serious 
adverse events and shown to contain potent synthetic cannabinoid receptor agonist drugs such 
as 5F-AKB48 and 5F-PB22. (1) 
 
Case presentation 
The ambulance service attended an emergency call to a homeless drop-in centre after an 18-
year-old male was found collapsed after reportedly smoking a legal high product called ‘Exodus 
Damnation’.  The male was found seated, slumped over a table.  On initial assessment he was 
pale and unresponsive (U), on the AVPU scale for assessing responsiveness (Alert, responds 
to Verbal stimuli, responds to Pain, Unresponsive), with slow, shallow breathing and an absent 
radial pulse.  
 
There was no indication of trauma and so to facilitate examination and treatment the patient 
was immediately repositioned supine on the floor.  His airway was unobstructed, respiratory 
rate was 10-12/min with oxygen saturations reading 91% on air.  High flow oxygen was 
administered at 15 litres/min via a non-rebreathing mask.  Despite this postural change there 
remained no radial pulse and a prolonged (>2 seconds) capillary refill.  A manual blood 
pressure measurement was attempted but ambient noise levels prevented any reading.   
 
During the disability assessment he remained unresponsive, with pupils dilated (blood shot) but 
reactive, blood glucose measured 6.2 mmol/l.  His temperature was 36.4oc, H.R. 100 – 110 
bpm.  A subsequent electronic blood pressure measurement of 87/50 mmHg prompted the 
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rapid placement of an intravenous cannula followed by a 250ml bolus of sodium chloride.  
Before administration of the fluid a 12 lead ECG was recorded which was unremarkable.  
 
In response to the oxygen therapy and fluid bolus the patient’s condition improved; oxygen 
saturation increased to 98% and systolic blood pressure to 101 mmHg.  The patient recovered 
becoming fully alert and orientated within approximately 2 minutes, subsequently refusing 
further assessment, treatment and transportation to the Emergency Department, despite 
repeated and prolonged efforts to encourage this. 
 
Discussion 
Recent reports suggest the number of new psychoactive substances (NPS) has been 
increasing annually since 2009. (2, 3) In Scotland, during 2013, 113 deaths were recorded 
where NPS were involved, 60 where they were implicated in or potentially contributed to death; 
16.5% of all drug related deaths. (4) None of these deaths were directly related to synthetic 
cannabinoids, however post-mortum detection and correlation with these substances can be 
problematic. (2)  There is an acknowledged limited evidence base on their toxic effects or care 
required. (1, 2 & 4) There are a two key points in this case worthy of discussion.   
 
Firstly, synthetic cannabinoids exert their actions on the central CB1 and/or peripheral CB2 
cannabinoid receptors. (5) The CB1 receptor being responsible for the psychotropic effects and 
CB2 as immune modulators. (5)  Patients may present with reduced consciousness, 
palpitations, agitation, seizures, headache, chest pain, sweating, hypertension and delusions.  
However, with the exception of reduced level of consciousness, most of the common adverse 
effects associated with synthetic cannabinoids were absent in this case. (5, 6) This atypical 
presentation caused uncertainty in determining the precise cause of collapse.  A small non-
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representative prevalence study conducted online in Scotland in 2014 found that 120 (17%) of 
the 657 respondents reported direct experience of NPS (having tried NPS previously or take it 
currently).  Of these, 26 % reported always (and 32% usually), using them alongside other 
substances; most commonly alcohol, cannabis or cocaine (7).  Whilst alternative substances 
may have contributed to the atypical presentation in the current case, the patient denied their 
use. Alternatively, it is recognised that the uncontrolled, haphazard manufacturing process of 
legal high products may cause uneven distribution of the active substance on the herbal 
material in some batches. (8) The potency of the substances present may therefore have 
contributed to this abnormal presentation.  
 
Secondly, the patient refused transportation to the ED.  Professional advice was sought from 
the local Emergency Department and Toxbase via Ambulance Control as it was recognised 
that these substances can have prolonged (several hours) and potentially life-threatening 
consequences. (4, 5) Both sources advised that the patient should be transported to the ED via 
ambulance for a period of observation. Despite informing the patient of these risks on-going 
care was persistently declined.  This was of significant concern to the attending ambulance 
clinicians who felt there was no viable alternative care pathway. 
 
It is often the case that neither the individual who has been intoxicated by NPS, nor those 
treating them, are certain of the nature of the substance consumed.  In this case, the 
systematic approach to pre-hospital assessment and treatment permitted the initial adverse 
features to be identified and treated effectively. (8) However, the successful treatment and 
rapid recovery permitted a prompt refusal of further care.  This was despite persuasive 
attempts by the attending ambulance clinicians to follow-up their care at the ED.  Therefore it is 
notable that for some individuals, ambulance clinicians are the only health care professionals 
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with whom they have contact and this should be recognised as an opportunity for intervention.  
Where such a refusal is made, follow-up care practices are brought sharply into focus, 
particularly where evidence exists to suggest a risk to the patient. (2, 4 & 5) There is some 
evidence that suggests a negative experience of NPS use may reduce the likelihood of future 
use. (7) Therefore, ambulance services may be in a unique position to capitalise on these 
negative experiences through appropriate encouragement of referral to primary care or 
provision of drug education advice.  It is perhaps a good time to re-examine existing referral 
practices for this, and similar, patient populations. 
 
Conclusion 
• Prehospital care clinicians must remain vigilant for the unusual presentations of NPS 
intoxications and be aware of this phenomenon.   
• Where presentations are atypical, it is essential that a systematic approach to 
assessment and treatment should be retained.  I 
• t has been identified that negative experiences of NPS may reduce future use.  For 
those patients with the capacity to refuse on-going support, ambulance services may 
be able to actively promote referral to support services for these potentially vulnerable 
individuals.  
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